More than a decade after first JAK approval, pharma looks to combination therapies to treat myelofibrosis. Pharma and biotech companies are looking to combination therapies for a new wave of treatments for the rare bone cancer myelofibrosis, building on the experience gathered over more than a decade with JAK inhibitors,… Read More
A new Case Study is now available to download from Cresset. In this Case Study, the authors test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system. Computational methods used include: Molecular Dynamics (MD) Water… Read More
In this Case Study, we test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system. Computational methods used include: Molecular Dynamics (MD) Water analysis solving the Ornstein-Zernike equation (3D-RISM) Alignment of ligands for FEP (Conformation Hunt… Read More
Sareum Holdings and Receptor.AI have entered into a strategic collaboration focused on accelerating the discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors. The goal of the agreement is to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, such as multiple sclerosis and Parkinson’s disease. Sareum’s previously… Read More
LEO Pharma has initiated the Phase IIa proof-of-concept DELTA NEXT trial to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle for mild to severe Palmoplantar Pustulosis (PPP). “The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey… Read More
Adding a new drug to standard care for stem cell transplant recipients may reduce graft-versus-host disease (GvHD), according to an early-stage clinical trial conducted at Washington University School of Medicine in St Louis. The trial showed that patients being treated for various blood cancers tolerated the… Read More
News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More
South Korean researchers have found that the use of Janus kinase (JAK) inhibitors as a treatment for atopic dermatitis (AD) is not associated with a greater risk of serious adverse events. While several biologic treatment approaches have been proposed in the recent years for the treatment… Read More
The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients. The authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both met the primary endpoint of the proportion of patients achieving SALT ≤20 (i.e.,… Read More
